KKR’s deal is a bet that financing needs from drug companies will continue to rise. - Michael Nagle/Bloomberg News. KKR has ...

Investment firm KKR (KKR) announced on Wednesday the acquisition of a majority stake in the biopharma royalty acquisition company, HealthCare Royalty Partners.

As part of the transaction, HCRx Chairman and CEO Clarke Futch will continue to lead the HCRx team and will maintain an ongoing substantial minority interest in HCRx.

KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company ...

Investment giant KKR reported a 9% rise in adjusted net income for the second quarter on Thursday, bolstered by an increase ...

KKR executives said strong momentum in their business gave them confidence on Thursday of beating earnings targets for 2026, ...

KKR continues its aggressive transformation from traditional private equity into a diversified financial powerhouse through strategic acquisitions and fund initiatives. The investment giant recently ...

Unicorns may be mythical beasts, but multibillion-dollar start-ups are alive and well and running wild on Wall Street. Design ...

Q2 2025 Earnings Call Transcript July 31, 2025 KKR & Co. Inc. beats earnings expectations. Reported EPS is $1.18, ...

Detailed price information for KKR & Company LP (KKR-N) from The Globe and Mail including charting and trades.

Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate ...